| scholarly article | Q13442814 |
| P50 | author | André Knottnerus | Q13429601 |
| P2093 | author name string | T Lemmens | |
| J Lodder | |||
| H J Schouten | |||
| J W van Ree | |||
| F Vermeer | |||
| B S Hellemons | |||
| M Langenberg | |||
| P2860 | cites work | Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 |
| Activation of blood coagulation in cancer: Trousseau's syndrome revisited. | Q33478010 | ||
| Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery. | Q34073217 | ||
| The natural history of lone atrial fibrillation. A population-based study over three decades | Q34186025 | ||
| Atrial fibrillation in elderly patients: prevalence and comorbidity in general practice | Q36601755 | ||
| Service provision and use of anticoagulants in atrial fibrillation. | Q36904817 | ||
| Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer | Q42281643 | ||
| Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators | Q43764537 | ||
| Canadian atrial fibrillation anticoaguiation (CAFA) study | Q43928649 | ||
| The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation | Q44153210 | ||
| Medical Decision Making By General Practitioners and Specialists | Q44190266 | ||
| Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis | Q49173787 | ||
| The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study | Q50542101 | ||
| Occurrence of arrhythmias in general practice. | Q50986589 | ||
| Tables of the number of patients required in clinical trials using the logrank test. | Q52722390 | ||
| Adaptive biased urn randomization in small strata when blinding is impossible. | Q52887164 | ||
| Primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation: the PATAF trial study design. | Q53344035 | ||
| Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation. | Q53394100 | ||
| Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. | Q54114563 | ||
| Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial | Q56659254 | ||
| Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators | Q67716302 | ||
| Stroke Prevention in Atrial Fibrillation Study. Final results | Q67925848 | ||
| Monitoring clinical trials with a conditional probability stopping rule | Q68138055 | ||
| Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy | Q69742234 | ||
| Aspirin wars: the optimal dose of aspirin prevent stroke | Q71042731 | ||
| The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics | Q71064706 | ||
| Antithrombotic therapy in atrial fibrillation | Q71732669 | ||
| Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials | Q72030226 | ||
| Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications | Q72566134 | ||
| Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group | Q72657107 | ||
| Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study | Q72671504 | ||
| Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Coumadin Aspirin Reinfarction Study (CARS) Investigators | Q73592736 | ||
| Thromboprophylaxis for atrial fibrillation | Q74452226 | ||
| Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators | Q74493798 | ||
| P433 | issue | 7215 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aspirin | Q18216 |
| atrial fibrillation | Q815819 | ||
| thromboembolism | Q891391 | ||
| P1104 | number of pages | 7 | |
| P304 | page(s) | 958-964 | |
| P577 | publication date | 1999-10-01 | |
| P1433 | published in | The BMJ | Q546003 |
| P1476 | title | Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin | |
| P478 | volume | 319 |
| Q28191806 | A review of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation |
| Q22306351 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation |
| Q37143256 | Advancement in antithrombotics for stroke prevention in atrial fibrillation |
| Q42072704 | Also the very elderly benefit from warfarin in atrial fibrillation |
| Q34196283 | American Heart Association/American College of Cardiology Foundation guide to warfarin therapy |
| Q50733256 | Anticoagulant treatment in atrial fibrillation |
| Q24245613 | Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter |
| Q34202452 | Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. |
| Q24245863 | Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack |
| Q28167527 | Anticoagulation for atrial fibrillation |
| Q37608499 | Anticoagulation in nonvalvular atrial fibrillation |
| Q35752603 | Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q35752573 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
| Q37990454 | Antithrombotic therapy for stroke prevention in atrial fibrillation and mechanical heart valves |
| Q26777365 | Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis |
| Q50663539 | Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. |
| Q38065252 | Atherosclerosis and thromboembolic risk in atrial fibrillation: focus on peripheral vascular disease. |
| Q28222928 | Atrial fibrillation and stroke prevention |
| Q35878355 | Bleeding profiles of anticoagulants, including the novel oral direct thrombin inhibitor ximelagatran: definitions, incidence and management |
| Q45975729 | Cardio-embolic stroke. |
| Q42787619 | Care is required with cost effectiveness approach |
| Q28194085 | Case report of paroxysmal atrial fibrillation and anticoagulation |
| Q42746443 | Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. |
| Q37528205 | Comparison of CHADS2 and CHA2DS2-VASC anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients |
| Q37015495 | Cost-Effectiveness of Percutaneous Closure of the Left Atrial Appendage in Atrial Fibrillation Based on Results From PROTECT AF Versus PREVAIL. |
| Q28484289 | Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation |
| Q38134680 | Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. |
| Q35636477 | Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials? |
| Q34233473 | Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation |
| Q40597502 | Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. |
| Q28081598 | Efficacy and safety of oral anticoagulants versus aspirin for patients with atrial fibrillation: a meta-analysis |
| Q36112764 | Exploratory Network Meta Regression Analysis of Stroke Prevention in Atrial Fibrillation Fails to Identify Any Interactions with Treatment Effect |
| Q45330277 | INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA). |
| Q37781101 | Intracranial and fatal bleeding according to indication for long-term oral anticoagulant therapy |
| Q28187842 | Long term anticoagulation or antiplatelet treatment. Only warfarin has been shown to reduce stroke risk in patients with atrial fibrillation |
| Q28167261 | Management of anticoagulant therapy for patients with prosthetic heart valves or atrial fibrillation |
| Q38389058 | Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation. |
| Q39850461 | Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. |
| Q28201631 | My health: whose responsibility? Low-dose aspirin and older people |
| Q34469069 | Neurologic manifestations of cardiogenic embolism: an update |
| Q42907047 | New Approaches to Stroke Prevention in Atrial Fibrillation |
| Q37697501 | Novel oral anticoagulants to prevent stroke in atrial fibrillation |
| Q24244298 | Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks |
| Q51926265 | Paper-based dosing algorithms for maintenance of warfarin anticoagulation. |
| Q38163036 | Pharmacologic and nonpharmacologic thromboprophylactic strategies in atrial fibrillation |
| Q26801820 | Preventing bleeding and thromboembolic complications in atrial fibrillation patients undergoing surgery |
| Q35938914 | Preventing stroke in atrial fibrillation patients - clinical utility of oral anticoagulants |
| Q37495942 | Prevention of Stroke by Antithrombotic Therapy in Patients with Atrial Fibrillation |
| Q35648111 | Prevention of cardioembolic stroke |
| Q37329482 | Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness |
| Q24801915 | Protocol for Birmingham Atrial Fibrillation Treatment of the Aged study, Etc. |
| Q33891646 | Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression |
| Q37802084 | Recent advances in oral anticoagulation for atrial fibrillation |
| Q33876319 | Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis |
| Q37780750 | Stroke prevention in atrial fibrillation patients |
| Q44672192 | Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial |
| Q28175307 | Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation |
| Q37666333 | The business case for quality improvement: oral anticoagulation for atrial fibrillation |
| Q38064758 | The challenge of antiplatelet therapy in patients with atrial fibrillation and heart failure |
| Q47220603 | The ethics of sample size: two-sided testing and one-sided thinking |
| Q40902478 | The new oral anticoagulants |
| Q34430437 | The oral anticoagulant saga: past, present, and future |
| Q34021780 | Treating individuals according to evidence: why do primary care practitioners do what they do? |
| Q37107710 | Use of anticoagulation in elderly patients with atrial fibrillation who are at risk for falls |
| Q33800650 | Using anticoagulation or aspirin to prevent stroke. Research was methodologically flawed |
| Q34351113 | Venous thrombosis and anticoagulant therapy |
| Q44971344 | Warfarin in the secondary prevention of thromboembolism in atrial fibrillation: impact of bioavailability on costs and outcomes |
| Q28219363 | Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial |
| Q45878562 | Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic International Normalized Ratio is not due to inflammation |
| Q80923321 | [Anticoagulants for patients with chronic auricular fibrillation: when are they indicated?] |
| Q50720552 | [Oral anticoagulation in symptomatic intracranial stenoses]. |
Search more.